J. Casellas

发表

Community-Acquired Klebsiella pneumoniae Bacteremia: Global Differences in Clinical Patterns

Herman Goossens, Victor L. Yu, Keith P. Klugman, 2002, Emerging infectious diseases.

Uncorrected proofs — not for distribution 5 A Latin American “ Point de Vue ” on the Epidemiology , Control , and Treatment Options of Infections Caused by Extended-spectrum Beta-lactamase Producers

J. Casellas, M. Quinteros, 2006 .

[Antibacterial drug resistance in Latin America: consequences for infectious disease control].

J. Casellas, 2011, Revista panamericana de salud publica = Pan American journal of public health.

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.

R. Cantón, P. Winokur, J. Casellas, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.

J. Casellas, E. Couto, C. Bantar, 2003, Diagnostic microbiology and infectious disease.

Plasmid-Mediated 1-Lactamase with Two Molecular Variants

J. Martínez-Beltrán, J. Pérez-Díaz, J. Casellas, 2022 .

pneumoniae Bacteremia: Global Differences in Clinical Patterns

H. Goossens, V. Yu, D. Paterson, 2002 .

CTX-M-12 β-Lactamase in a Klebsiella pneumoniae Clinical Isolate in Colombia

J. Quinn, K. Lolans, J. Ayala, 2004, Antimicrobial Agents and Chemotherapy.

Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: Recommendations from an International Working Group

P. Hsueh, I. Gould, A. Endimiani, 2013, Journal of chemotherapy.

Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening.

H. Sader, J. Casellas, M. Guzmán-Blanco, 2000, Infectious disease clinics of North America.

In vitro activity of the new ketolide ABT-773 against community acquired respiratory tract isolates and Viridans Streptococci.

J. Casellas, M. Visser, L. Gliosca, 2002, Diagnostic microbiology and infectious disease.

Comparative In Vitro Activity of Trovafloxacin Against Gram-Positive and Gram-Negative Clinical Isolates from Argentina

M. Galas, A. Rossi, J. Casellas, 1999, Drugs.

Development and internal validation of a predictive model for COVID-19 mass screening based on symptoms and a simple olfactory test

Eduard Llobet, Youcef Azeli, Alberto Fernández, 2021 .

Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory

Victor L. Yu, Keith P. Klugman, Robert A. Bonomo, 2001, Journal of Clinical Microbiology.

Serum anti-Escherichia coli antibodies and urinary beta-glucuronidase for the diagnosis and control of evolution of urinary infection during pregnancy.

J. Casellas, R. A. Rubí, J. Vinacur, 1974, American journal of obstetrics and gynecology.

Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants

F. Baquero, K. Bush, J. Martínez-Beltrán, 1994, Antimicrobial Agents and Chemotherapy.

Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases

I. Stemplinger, J. Casellas, A. Bauernfeind, 1996, Antimicrobial agents and chemotherapy.

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

H. Goossens, L. Rice, V. Yu, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase

I. Stemplinger, J. Casellas, A. Bauernfeind, 1996, Antimicrobial agents and chemotherapy.

Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

H. Goossens, V. Yu, D. Paterson, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum -Lactamase Production in Nosocomial Infections

H. Goossens, L. Rice, V. Yu, 2004, Annals of Internal Medicine.

Comparative In Vitro Activity of Tigecycline Against Aerobic and Facultative Isolates Recovered from Hospitalized Patients: An Argentinean Multicenter Study

J. Casellas, C. Bantar, F. Duret, 2007, Journal of chemotherapy.

INTERNATIONAL PRASPECTIVE STUDY OF KLEBSIELLA PNEUMONIAE IN NOSOCOMIAL BACTEREMIA:IMPLICATIONS OF EXTENDEDSPECTERUM- BETA LACTAMASE PRODUCTION IN NOSOCOMIAL INFECTIONS

H. Goossens, D. Paterson, S. Mohapatra, 2004 .

The sleeping giant. Antimicrobial resistance.

J. Casellas, M. G. Blanco, M. E. Pinto, 1994, Infectious disease clinics of North America.

Biochemical Characterization of PER-2 and Genetic Environment of blaPER-2

J. Ayala, J. Casellas, J. D. Di Conza, 2007, Antimicrobial Agents and Chemotherapy.

CTX-M-12 beta-lactamase in a Klebsiella pneumoniae clinical isolate in Colombia.

J. Quinn, K. Lolans, J. Ayala, 2004, Antimicrobial agents and chemotherapy.

Prevalence of extended-spectrum β-lactamases in South America

J. Casellas, M. Villegas, M. Quinteros, 2008 .

Prevalence of extended-spectrum beta-lactamases in South America.

J. Casellas, M. Villegas, M. Quinteros, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Incidence of strains producing extended spectrum β-lactamases in Argentina

J. Casellas, M. Goldberg, 1989, Infection.

Review of Pharmacokinetic, Pharmacodynamic and Clinical Studies with a Modern Combination of Amoxicillin/Sulbactam

J. Casellas, C. Bantar, H. Arenoso, 2006, Chemotherapy.

Urine inhibitory titers against resistant Escherichia coli isolates after oral amoxicillin-sulbactam.

J. Casellas, M. Visser, H. Arenoso, 2003, Medicina.